Evidence map›Paper›PMID 42724635›Full record

ReviewFrontiers in medicine2026

Advanced and underlying therapeutic strategies in transformed small cell lung cancer.

Mingfeng Wei, Zheng Li, Kaiyuan Zhu, Shixiang Guo, Lefei Hu, Fuzhi Yang, Xiaoyu Chen, Xuelin Zhang, Shuai Jiang, Xunxia Zhu and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mingfeng Wei *Shanghai Key Laboratory of Clinical Geriatric Medicine, Affiliated Huadong Hospital, Fudan University, Shanghai, China.
Zheng Li *Shanghai Key Laboratory of Clinical Geriatric Medicine, Affiliated Huadong Hospital, Fudan University, Shanghai, China.
Kaiyuan ZhuShanghai Key Laboratory of Clinical Geriatric Medicine, Affiliated Huadong Hospital, Fudan University, Shanghai, China.
Shixiang GuoShanghai Key Laboratory of Clinical Geriatric Medicine, Affiliated Huadong Hospital, Fudan University, Shanghai, China.
Lefei HuShanghai Key Laboratory of Clinical Geriatric Medicine, Affiliated Huadong Hospital, Fudan University, Shanghai, China.
Fuzhi YangShanghai Key Laboratory of Clinical Geriatric Medicine, Affiliated Huadong Hospital, Fudan University, Shanghai, China.
Xiaoyu ChenShanghai Key Laboratory of Clinical Geriatric Medicine, Affiliated Huadong Hospital, Fudan University, Shanghai, China.
Xuelin ZhangShanghai Key Laboratory of Clinical Geriatric Medicine, Affiliated Huadong Hospital, Fudan University, Shanghai, China.
Shuai JiangShanghai Key Laboratory of Clinical Geriatric Medicine, Affiliated Huadong Hospital, Fudan University, Shanghai, China.
Xunxia ZhuShanghai Key Laboratory of Clinical Geriatric Medicine, Affiliated Huadong Hospital, Fudan University, Shanghai, China.
Xiaoyong ShenShanghai Key Laboratory of Clinical Geriatric Medicine, Affiliated Huadong Hospital, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transformed small-cell lung cancer (T-SCLC) is a clinically important form of histologic transformation and a mechanism of acquired resistance in non-small-cell lung cancer (NSCLC). It is associated with poor prognosis, with a median overall survival of only about 9-13 months. This review summarizes recent advances in the mechanisms, diagnosis, monitoring, and treatment of T-SCLC. Repeat biopsy remains the gold standard for confirming histologic transformation, whereas molecular profiling and liquid biopsy may facilitate early detection and longitudinal disease monitoring. Platinum-etoposide remains the most commonly used clinical standard after transformation, but its benefit is typically transient and durable disease control remains uncommon. Continuation of

Indexed as

advanced therapyhistologic transformationlineage plasticitylung cancertargeted therapy

Identifiers

PMID42724635
PMCPMC13560167

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.